Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Up Almost 11 Percent on BioReliance Sale, EPS Performance

NEW YORK (GenomeWeb News) — Shares in Invitrogen were up nearly 10.5 percent at $66.73 in mid-afternoon trading after the company reported yesterday it would sell its flagging BioReliance business, and that its fourth-quarter earnings per share beat Wall Street expectations.
 
As GenomeWeb News reported this morning, Invitrogen said it plans to sell the BioReliance unit to Avista Capital Partners for $210 million as part of Invitrogen’s ongoing plan to better organize its acquired components, the companies said late yesterday.  
 
Separately yesterday, Invitrogen reported weak fourth-quarter revenue growth as R&D spending decreased 7.6 percent and net income dropped 300 percent on a variety of one-time charges. However, earnings per share beat analysts' estimates.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.